TriSalus Life Sciences To Host Virtual KOL Event On Thyroid Disease And PED-TAE TriNav Infusion Approach On December 15, 2025 At 2:00pm ET

Benzinga · 1d ago

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and current treatment landscape for symptomatic thyroid disease. To register, click here.

The event will provide an overview of the TriNav Infusion System and its Pressure-Enabled Delivery for Thyroid Artery Embolization (PED-TAE) approach. PED-TAE targets the inferior thyroid arteries and aims to reduce gland size and alleviate symptoms in patients who are not candidates for surgery or conventional therapies.

A question and answer session will follow the formal presentations.